Patents Assigned to Algernon Pharmaceuticals Inc.
  • Compositions and methods for treating non-alcoholic steatohepatitis
    Patent number: 11744808
    Abstract: Cepharanthine, Repirinast, Ifenoprodil Hemitartrate, Bromantane, Actarit, Lobenzarit, Irsogladine, Istradefylline, Trapadil, Bemithyl, and are used for treating or prophylaxis of lobular inflammation, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis in a subject.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: September 5, 2023
    Assignee: ALGERNON PHARMACEUTICALS INC.
    Inventor: Mark Williams
  • Use of Glutamate 2B Receptor Antagonists and Sigma Receptor Agonists as Antitussives
    Publication number: 20220378769
    Abstract: The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigma receptor agonists include fluvoxamine, fluoxetine, excitalpram, and donepezil.
    Type: Application
    Filed: March 6, 2020
    Publication date: December 1, 2022
    Applicant: Algernon Pharmaceuticals Inc.
    Inventor: Mark Williams